Gland Pharma Limited (GLAND)
ISIN: - Industry: Drug Manufacturers—General Sector: Healthcare Website
2874.65
-108.95(-3.65%)

Gland Pharma Limited engages in the development, manufacture, and marketing of injectable-focused generic liquid parenteral products. The company's primary molecules include heparin sodium, enoxaparin sodium, rocuronium bromide, and daptomycin injections, as well as others. It offers its products under various therapeutic categories, such as anti-infectives, anesthetics, anti-coagulants and their antidotes, anti-malarial, cardiology, gastro-intestinal, pain management, hormones and related drugs, fertility supplements, Gnrh agonists and antagonists, anti-neoplastic, gynecological, neurological and central nervous system, respiratory, blood related, ophthalmological and otological, pain/analgesics, orthopedics, hematinic, vitamins/minerals/nutrients, and others. The company also provides contract development services. It sells its products primarily under a business to business in the United States, Europe, Canada, Australia, India, and internationally. The company was incorporated in 1978 and is based in Hyderabad, India. Gland Pharma Limited is a subsidiary of Fosun Pharma Industrial Pte. Ltd.

Pricing Updates

TODAY'S HIGH

3022.35

TODAY'S LOW

2862

52 WEEK HIGH

4350

52 WEEK LOW

2801

Major Holders

% of Shares Held by
All Insider

67.76%

% of Shares Held by
Institutions

20.56%

% of Float Held by
Institutions

63.79%

Number of Institutions
Holding Shares

82

Company Overview

MARKET CAP

47831.59 Cr.

ETERPRISE VALUE

47129.40 Cr.

NO. OF SHARES

16.45 Cr.

BOOK VALUE

435.613

DIV. YIELD

None%

DEBT

4.74 Cr.

GROSS PROFIT

0

CASH

3248.31 Cr.

REVENUE

''

REVENUE/SHARE

None

OHLC Chart 1y 2y 5y 10y

Price Chart

1d 1w 1m 3m 6m 1Yr 2Yr 5Yr

Volumes Chart

1d 1w 1m 3m 6m 1Yr 2Yr 5Yr

Cashflows

ParticularsMar 2022Mar 2021Mar 2020Mar 2019
Investments0-1357.59 Cr.-638.74 Cr.-218.74 Cr.
Change To Liabilities0142.81 Cr.-214.67 Cr.113.01 Cr.
Total cashflows from Investing Activities0-1524 Cr.-766.07 Cr.-314.13 Cr.
Net Borrowings0-1.01 Cr.-62 Lakhs-50.70 Lakhs
Total Cash from Financing Activities01238.46 Cr.-6.87 Cr.-3.12 Cr.
Other Liabilities051.40 Lakhs59.65 Cr.-22.01 Cr.
Total Assets01241.80 Cr.1241.80 Cr.1241.80 Cr.
Net Income0996.96 Cr.772.85 Cr.451.85 Cr.
Change in Cash0322.96 Cr.-66.90 Cr.-136.43 Cr.
Effect of Exchange Rate03.57 Cr.5.10 Cr.-4.43 Cr.
Total Cash from Operating Activities0604.92 Cr.700.93 Cr.185.25 Cr.
Depreciation098.78 Cr.94.58 Cr.82.12 Cr.
Other Cashflows from Investing Activities061.93 Cr.43.44 Cr.39.80 Cr.
Dividends Paid0000
Change to Inventory0-518.88 Cr.155.59 Cr.-399.04 Cr.
Change to Account Receivables0-60.20 Cr.-80.51 Cr.-45.89 Cr.
Other Cashflows from Financing Activities0-2.33 Cr.-6.25 Cr.-2.61 Cr.
Change to Net Income0-55.05 Cr.-86.56 Cr.5.22 Cr.
Capital Expenditures0-228.77 Cr.-194.66 Cr.-135.74 Cr.

Financials

ParticularsMar 2022Mar 2021Mar 2020Mar 2019
Research DevelopmentNoneNoneNoneNone
Effect of Accounting ChargesNoneNoneNoneNone
Income Before Tax01334.81 Cr.992.86 Cr.686.27 Cr.
Minority InterestNoneNoneNoneNone
Net Income01203.44 Cr.860.88 Cr.624.38 Cr.
Selling General Administrative0312.18 Cr.278.42 Cr.223.75 Cr.
Gross Profit01853.21 Cr.1417.76 Cr.1080.17 Cr.
Ebit01203.44 Cr.860.88 Cr.624.38 Cr.
Operating Income01203.44 Cr.860.88 Cr.624.38 Cr.
Other Operating Expenses0238.52 Cr.182.25 Cr.140.44 Cr.
Interest Expense0-2.91 Cr.-6.25 Cr.-2.61 Cr.
Extraordinary ItemsNoneNoneNoneNone
Non RecurringNoneNoneNoneNone
Other ItemsNoneNoneNoneNone
Income Tax Expense0337.84 Cr.220 Cr.234.42 Cr.
Total Revenue03462.87 Cr.2633.24 Cr.2044.20 Cr.
Total Operating Expenses02259.43 Cr.1772.36 Cr.1419.82 Cr.
Cost of Revenue01609.66 Cr.1215.47 Cr.964.02 Cr.
Total Other Income Expense Net0131.36 Cr.131.98 Cr.61.89 Cr.
Discontinued OperationsNoneNoneNoneNone
Net Income from Continuous Ops.0996.96 Cr.772.85 Cr.451.85 Cr.
Net Income Applicable to Common Shares0996.96 Cr.772.85 Cr.451.85 Cr.

Balance Sheet

ParticularsMar 2022Mar 2021Mar 2020Mar 2019
Intangible Assets0000
Capital Surplus01840.10 Cr.588.99 Cr.588.99 Cr.
Total Liabilities0592.84 Cr.439.80 Cr.661.55 Cr.
Stock Holder Equity05903.24 Cr.3646.23 Cr.2861.99 Cr.
Minority Interest0000
Other Liabilities080.04 Cr.64.31 Cr.61.28 Cr.
Total Assets06496.08 Cr.4086.03 Cr.3523.54 Cr.
Common Stock016.35 Cr.15.49 Cr.15.49 Cr.
Retained Earnings04025.80 Cr.3028.84 Cr.2255.86 Cr.
Other Liabilities075.61 Cr.75.78 Cr.122.77 Cr.
Good Will0000
Treasury Stock020.97 Cr.12.90 Cr.1.64 Cr.
Other Assets080.40 Cr.83.18 Cr.113.22 Cr.
Cash0492.46 Cr.169.49 Cr.236.40 Cr.
Current Liabilities0512.52 Cr.359.02 Cr.532.76 Cr.
Long Term Asset Charges0000
Short Long Term Debt013.50 Lakhs89.10 Lakhs53 Lakhs
Other Stockholder Equity020.97 Cr.12.90 Cr.1.64 Cr.
Property Plant Equipment01292.03 Cr.1156.56 Cr.1052.87 Cr.
Total Cur. Assets05123.64 Cr.2846.29 Cr.2357.45 Cr.
Long Term Investments0000
Net Tangible Assets05903.24 Cr.3646.23 Cr.2861.99 Cr.
Short Term Investments02510.68 Cr.1142.72 Cr.484.34 Cr.
Net Receivables0744.46 Cr.664.39 Cr.552.04 Cr.
Long Term Debt03.93 Cr.4.06 Cr.4.96 Cr.
Inventory01288.16 Cr.771.35 Cr.922.71 Cr.
Accounts Payable0400.72 Cr.249.09 Cr.446.19 Cr.

New Offers


Upstox offer
Upstox

Open a demat account through us and get the account opening charges waived off

open paperless account